Open AccessAntibody Testing Strategies for Deceased Donor Kidney Transplantation After Immunomodulatory Therapy
Author(s) -
Chih Hung Lai,
Kai Cao,
Geraldine Ong,
Mehrnoush Naim,
Qi Wang,
James Mirocha,
Ashley Vo,
Stanley C. Jordan,
Nancy L. Reinsmoen
Publication year - 2011
Publication title -
transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e31821eab8a
Subject(s) - medicine , antibody , rituximab , transplantation , antigen , human leukocyte antigen , immunology , kidney transplantation , donor specific antibodies , gastroenterology
Immunomodulatory protocols including intravenous immunoglobulin/rituximab (IVIG/R) are employed to decrease anti-human leukocyte antigen (HLA) antibody levels for patients broadly sensitized to HLA and increase chances for transplantation with a compatible deceased donor (DD). The aim of our study was to identify the optimal antibody levels allowing for selection of compatible DDs for these sensitized patients.